Previous Article | Next Article 
Journal of Clinical Microbiology, March 1999, p. 858-861, Vol. 37, No. 3
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Comparative Study of Susceptibilities of Germinated and
Ungerminated Conidia of Aspergillus fumigatus to Various
Antifungal Agents
Elias K.
Manavathu,*
Jessica
Cutright, and
Pranatharthi H.
Chandrasekar
Division of Infectious Diseases, Department
of Medicine, Wayne State University School of Medicine, Detroit,
Michigan 48201
Received 3 August 1998/Returned for modification 22 September
1998/Accepted 1 December 1998
 |
ABSTRACT |
Conidia are used as inocula for the in vitro susceptibility testing
of Aspergillus fumigatus. Since the MIC is defined on the
basis of visible mycelial growth, conidia should germinate and produce
sporelings (germinated conidia) for monitoring of the growth inhibition
and fungicidal activity of a drug. If a compound is capable of
inhibiting germination of conidia while affecting or not affecting the
growth of the organism, the MIC obtained will be the concentration of
the drug required for the inhibition of conidial germination but not
necessarily that required for inhibition of the growth of the organism.
We investigated the susceptibility of germinated and ungerminated
conidia to amphotericin B, itraconazole, voriconazole, and SCH56592.
The MICs of various antifungal agents for germinated conidia
were almost identical to those obtained for ungerminated conidia. In
addition, both the germinated and ungerminated conidia were killed with
almost equal efficiency by all of the compounds tested when exposed to the drugs for 24 h. These results suggest that either germinated or ungerminated conidia could be used as inocula for in vitro susceptibility studies of A. fumigatus with identical results.
 |
TEXT |
The availability of a standardized
method for the in vitro susceptibility testing of filamentous fungi is
essential for inter- and intralaboratory comparisons of MICs of various
antifungal agents. MIC comparisons are often useful for the
identification of clinical isolates with reduced susceptibility to
antifungal agents, as well as for examining the correlation between
treatment failure and in vitro resistance to antifungal agents. Efforts have been recently made to standardize a technique of MIC determination for filamentous fungi (2, 3, 9, 10) based on the method recommended by the National Committee for Clinical Laboratory Standards
for the susceptibility testing of pathogenic yeasts (7). As
a matter of convenience and for reproducibility, conidial suspensions
have been used as the source of inocula for MIC determination for
various Aspergillus species. Overall, use of conidia has
resulted in excellent reproducibility of the results obtained in
different laboratories (1, 5, 8, 11). However, the
suitability of using ungerminated conidia as inocula for MIC
determination for Aspergillus species has been a matter of
concern. The lack of growth obtained in the presence of an antifungal
agent may be due to inhibition of conidial germination or inhibition of growth. Are the growth inhibition and the fungicidal activity of an
antifungal agent the same for germinated and ungerminated conidia? To
answer this question, we examined the growth inhibition and fungicidal
activities of various antifungal agents against germinated and
ungerminated conidia of Aspergillus fumigatus.
Ten clinical isolates (W73355, F55064, W27023, T53454, W43719, H55622,
H70853, W63928, H38167, and W33299) of A. fumigatus obtained
from the Microbiology Laboratory of the Detroit Medical Center were
used in this study. The original cultures obtained on Sabouraud
dextrose agar slants were subcultured on the same medium to check the
purity and viability of the culture. For long-term storage,
cultures were kept as conidial suspensions in 25%
glycerol at
70°C. Cultures were grown on Sabourand dextrose agar
for 6 days at 35°C for the production of conidia. The conidia were
collected, and the density of the conidial suspension was determined as
described previously (5).
For the germination assay, fresh conidia were resuspended in
peptone-yeast extract-glucose (PYG; 1 g of peptone, 1 g of
yeast extract, and 3 g of glucose per liter of distilled water)
medium (106 conidia/ml) and incubated at 35°C with gentle
agitation (160 rpm) on a gyratory shaker. At various time intervals,
10-µl aliquots were removed and the numbers of germinated conidia
were assessed by hemocytometer counting. Percent germination was
calculated and graphed against time of incubation in PYG broth. Conidia
were counted at a magnification of ×400, and a total of 200 conidia per field were counted. The counting was done three times, and the mean
value of these three independent counts was used to obtain the percent germination.
The MICs of various antifungal agents for germinated and ungerminated
conidia were determined by broth macrodilution. Briefly, fresh conidia
were resuspended in 50 ml of PYG broth at a density of
106/ml and allowed to germinate for 8 h as
described above. One-milliliter aliquots of the germinated and
ungerminated conidial suspensions were diluted 50-fold to
obtain a cell density of 2 × 104 conidia/ml,
and the MICs of various antifungal agents were determined in PYG
broth as previously described (5). The MIC was defined as
the drug concentration that inhibited visible growth completely. It was
important to keep the conidial density at 106 conidia/ml
for optimum germination. Higher conidial densities produced lower
germination frequencies (presumably due to a population effect). A
density lower than 106 conidia/ml posed problems for
accurate counting, kill curve experiments, and MIC studies.
For the kill curve experiments, 106 germinated (8 h)
and ungerminated conidia were incubated in 1 ml of PYG broth at
35°C for 24 h in the presence of various antifungal agents (5 µg/ml). At the end of the incubation period, the cell suspension was
diluted 10- to 1,000-fold and 0.1-ml aliquots were spread on PYG agar plates. The plates were incubated at 35°C for 48 h, and the
numbers of CFU were determined. Each treatment was done in duplicate, and the experiment was repeated six times by using three different clinical isolates.
Amphotericin B (batch 20-914-29670) was obtained from the Squibb
Institute for Medical Research, Princeton, N.J. Itraconazole (R51 211;
batch STAN-9304-005-1) was from Janssen Pharmaceutica, Beerse, Belgium. Voriconazole was from Pfizer Pharmaceuticals (New York, N.Y.), and SCH56592 was obtained from the
Schering-Plough Research Institute (Kenilworth, N.J.). Compounds were
dissolved in dimethyl sulfoxide at a concentration of 1 mg/ml and
stored as 0.25-ml aliquots at
20°C. The frozen stock was thawed at
room temperature and vortexed gently several times to ensure that any crystals present were completely dissolved before use. Comparable concentrations of dimethyl sulfoxide were used to examine its effect on
the growth of A. fumigatus. No detectable inhibition of
growth occurred at the concentrations used. Since amphotericin B is
light sensitive, the stock solutions and the MIC tubes were covered
with aluminum foil to prevent light exposure. For all antifungal
agents, a concentration range of 0.125 to 16 µg/ml was used for MIC determination.
As shown in Fig. 1, the germination of
A. fumigatus conidia at 35°C in PYG broth was a multistep
process. During the initial 4 h of incubation, the conidia
underwent a significant increase in volume by swelling, and the
diameter of the conidia increased approximately twofold compared to
that of the resting conidia. The swelling of the conidia was followed
by the appearance of a small protuberance on the conidial cell wall,
and the conidium was now primed for polarized growth. The appearance of
the protuberance was followed by the formation of a germ tube, and
10.67% ± 2.16% of the conidia germinated and produced sporelings
(germinated conidia with the length of the germ tube equal to or
greater than the diameter of swollen conidia) within 6 h after
incubation. The emergence of germ tubes occurred rapidly after 6 h
of incubation, and 96.5% ± 2.47% of the conidia were germinated by
8 h of incubation in PYG broth at 35°C.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 1.
Photomicrographs (original magnification, ×400) (A) and
kinetics (B) of germinating conidia of A. fumigatus W73355
in PYG broth at 35°C. The experiment was repeated six times by using
three different clinical isolates; similar results were obtained for
all isolates. The data shown were obtained in a typical experiment with
isolate W73355. Each point on the graph represents the mean of
triplicate determinations, and the standard deviation was <5% of the
mean value.
|
|
A comparison of the MICs of amphotericin B, itraconazole, voriconazole,
and SCH56592 obtained for germinated and ungerminated conidia is shown
in Table 1. No significant change in MICs
was obtained with the germinated conidia. The maximum change obtained was ±1 dilution. However, the conidia should be germinated more or
less synchronously, within a period of 8 h of incubation, to obtain reproducible results. Longer incubation resulted in rapid growth, and the mycelial mass increased markedly. This increase in
mycelial mass resulted in a decrease in the antibiotic-to-fungal-mass ratio which, in turn, resulted in lower effective concentrations of the
drug. It has been shown that the MICs of antifungal agents for
filamentous fungi are dependent on the nature (4) and size (5) of the inoculum. Thus, the occurrence of a higher MIC
for hyphae is due not necessarily to their reduced susceptibility to a
drug but rather to an increase in mycelial mass.
The fungicidal activities of various antifungal agents against
germinated and ungerminated conidia of A. fumigatus are
shown in Fig. 2. We used approximately 10 times the MIC of the compounds for kill curve experiments.
Amphotericin B, itraconazole, voriconazole, and SCH56592 at 5 µg/ml
killed 99.36% ± 0.74%, 96.79% ± 0.83%, 97.77% ± 0.19%,
and 98.74% ± 0.84%, respectively, of the ungerminated conidia after
24 h of exposure. No significant difference in the killing ability
of these antifungal agents (amphotericin B, 99.88% ± 0.056%;
itraconazole, 97.27% ± 1.55%; voriconazole, 97.38% ± 0.69%;
SCH56592, 94.86% ± 5.95%) against germinated conidia was obtained.
In addition to A. fumigatus W73355, we examined the susceptibility of two additional clinical isolates (F55064 and W27023)
to various antifungal agents. Both germinated and ungerminated conidia
from these two isolates also provided similar results, suggesting that
the observed results were not a strain-dependent phenomenon. As opposed
to the common notion that azoles are generally fungistatic agents and
not fungicidal, we previously demonstrated (6) that
triazoles such as itraconazole and voriconazole are fungicidal for
Aspergillus species, including A. fumigatus. Our present data confirm the previous finding and further show that the
observed killing was not restricted to resting conidia but extended to
germinated conidia as well.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 2.
Fungicidal activities of amphotericin B (AMB) and
various triazoles on germinated and ungerminated conidia of A. fumigatus. The experiment was repeated three times with isolate
W73355 and twice with isolates F55064 and W27023. Similar results were
obtained each time with all three isolates. The data shown were
obtained in a typical experiment with isolate W73355. Each
histogram represents the mean of duplicate determinations, and
the standard deviations were 50% of the mean value in all cases.
ITZ, itraconazole; VCZ, voriconazole; SCH, SCH56592.
|
|
One of the concerns in the development of a standard method for the in
vitro susceptibility testing of filamentous fungi is the nature of the
inoculum. Vegetative mycelia have several disadvantages. One, it is
important to dispense the inoculum uniformly throughout the test
samples, since the MIC will be greatly dependent on the inoculum size.
Second, Guarro et al. (4) noted that the use of vegetative
mycelia produced consistently higher MICs than did the use of conidia.
Third, since filamentous fungi grow by apical elongation, major
portions of the hyphae away from the tips are metabolically inactive.
Consequently, if mycelia are used as inocula, the compounds are tested
against relatively nongrowing parts of the organism. A fourth
consideration is the difficulty of dealing rapidly with large numbers
of samples for susceptibility testing in clinical laboratories.
Susceptibility testing will be time consuming and cumbersome if
performed with vegetative mycelia.
The use of conidia is an attractive option for in vitro susceptibility
testing. It is comparatively fast and efficient, and precise amounts of
the inocula can be delivered rapidly for MIC testing. However, a
serious concern is the appropriateness of using dormant conidia for MIC
determinations. The conidia must first germinate for the antifungal
agents to inhibit their visible growth, which is the criterion for the
definition of the MIC. The whole premise is based on the assumption
that the germination process of the conidia per se is not affected by
the test compounds. If the germination process is affected while growth
is or is not affected, then the use of dormant conidia will provide
erroneous results. It is therefore important to establish that both
germinated and ungerminated conidia are equally susceptible to the
inhibitory action of the antifungal agents commonly used, in
particular, azoles and polyenes. The MICs of other compounds which may
have activity against macromolecular synthesis (e.g., nucleic acid and
protein syntheses) will be affected by inhibiting spore germination, since the germination of spores involves the synthesis of RNA and
proteins. Our studies show that both germinated and ungerminated conidia of A. fumigatus are equally susceptible to the
inhibitory and fungicidal activities of polyene and azole compounds.
The use of conidia as inocula may not result in MICs of azoles and polyenes due to inhibition of spore germination. However, when screening new compounds for activity against filamentous fungi by using
conidia as inocula, it is useful to test their effect on germinated and
ungerminated conidia to confirm that the antifungal activity is due to
inhibition of growth and not to inhibition of spore germination.
 |
ACKNOWLEDGMENTS |
We thank Pfizer Pharmaceuticals and the Schering-Plough Research
Institute, respectively, for providing voriconazole and SCH56592. Also,
we thank William Brown of the Microbiology Laboratory, Detroit Medical
Center, for providing the clinical isolates of A. fumigatus used in this study.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, 427 Lande Building, 550 E. Canfield, Detroit, MI 48201. Phone: (313) 577-1931. Fax: (313) 993-0302. E-mail:
aa1388{at}wayne.edu.
 |
REFERENCES |
| 1.
|
Denning, D. W.,
K. Venkateswarlu,
K. L. Oakley,
M. J. Anderson,
N. J. Manning,
D. A. Stevens,
D. W. Warnock, and S. L. Kelly.
1997.
Itraconazole resistance in Aspergillus fumigatus.
Antimicrob. Agents Chemother.
41:1364-1368[Abstract].
|
| 2.
|
Espinel-Ingroff, A.,
K. Dawson,
M. Pfaller,
E. Anaissie,
B. Breslin,
D. Dixon,
A. Fothergill,
J. Peter,
M. Rinaldi, and T. Walsh.
1995.
Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.
Antimicrob. Agents Chemother.
39:314-319[Abstract/Free Full Text].
|
| 3.
|
Espinel-Ingroff, A.,
J. H. Rex,
R. Bowden,
P. Menezes,
M. Bartlett,
M. McGinnis,
C. Cooper,
F. C. Odds,
M. Pfaller,
S. A. Messer,
P. W. Nelson,
M. G. Rinaldi,
A. Fothergill,
G. Shankland,
T. J. Walsh,
J. Peter,
I. Weitzman, and N. X. Chin.
1996.
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.
J. Clin. Microbiol.
35:139-143[Abstract].
|
| 4.
|
Guarro, J.,
C. Llop,
C. Aguilar, and I. Pujol.
1997.
Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi.
Antimicrob. Agents Chemother.
41:2760-2762[Abstract].
|
| 5.
|
Manavathu, E. K.,
G. J. Alangaden, and S. A. Lerner.
1996.
A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus.
Can. J. Microbiol.
42:960-964[Medline].
|
| 6.
|
Manavathu, E. K.,
J. L. Cutright, and P. H. Chandrasekar.
1998.
Organism-dependent fungicidal activity of azoles.
Antimicro. Agents Chemother.
42:3018-3021[Abstract/Free Full Text].
|
| 7.
|
National Committee for Clinical Laboratory Standards.
1997.
Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A.
National Committee for Clinical Laboratory Standards, Villanova, Pa.
|
| 8.
|
Oakley, K. L.,
G. Morrissey, and D. W. Denning.
1997.
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.
Antimicrob. Agents Chemother.
41:1504-1507[Abstract].
|
| 9.
|
Odds, F. C.,
F. V. Gerven,
A. Espinel-Ingroff,
M. S. Bartlett,
M. A. Ghannoum,
M. V. Lancaster,
M. A. Pfaller,
J. H. Rex,
M. G. Rinaldi, and T. J. Walsh.
1998.
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.
Antimicrob. Agents Chemother.
42:282-288[Abstract/Free Full Text].
|
| 10.
|
Pfaller, M. A.,
J. H. Rex, and M. G. Rinaldi.
1997.
Antifungal susceptibility testing: technical advances and potential clinical applications.
Clin. Infect. Dis.
24:776-784[Medline].
|
| 11.
|
Pujol, I.,
J. Guarro,
C. Llop,
L. Soler, and J. Fernandez-Ballart.
1996.
Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi.
Antimicrob. Agents Chemother.
40:2106-2110[Abstract].
|
Journal of Clinical Microbiology, March 1999, p. 858-861, Vol. 37, No. 3
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Serbina, N. V., Cherny, M., Shi, C., Bleau, S. A., Collins, N. H., Young, J. W., Pamer, E. G.
(2009). Distinct Responses of Human Monocyte Subsets to Aspergillus fumigatus Conidia. J. Immunol.
183: 2678-2687
[Abstract]
[Full Text]
-
Bellanger, A.-P., Millon, L., Khoufache, K., Rivollet, D., Bieche, I., Laurendeau, I., Vidaud, M., Botterel, F., Bretagne, S.
(2009). Aspergillus fumigatus germ tube growth and not conidia ingestion induces expression of inflammatory mediator genes in the human lung epithelial cell line A549. J Med Microbiol
58: 174-179
[Abstract]
[Full Text]
-
Richards, T. S., Oliver, B. G., White, T. C.
(2008). Micafungin activity against Candida albicans with diverse azole resistance phenotypes. J Antimicrob Chemother
62: 349-355
[Abstract]
[Full Text]
-
Chaturvedi, A. K., Kavishwar, A., Shiva Keshava, G. B., Shukla, P. K.
(2005). Monoclonal Immunoglobulin G1 Directed against Aspergillus fumigatus Cell Wall Glycoprotein Protects against Experimental Murine Aspergillosis. CVI
12: 1063-1068
[Abstract]
[Full Text]
-
Krishnan, S., Manavathu, E. K., Chandrasekar, P. H.
(2005). A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother
55: 914-920
[Abstract]
[Full Text]
-
Araujo, R., Rodrigues, A. G.
(2004). Variability of Germinative Potential among Pathogenic Species of Aspergillus. J. Clin. Microbiol.
42: 4335-4337
[Abstract]
[Full Text]
-
Araujo, R., Rodrigues, A. G., Pina-Vaz, C.
(2004). A fast, practical and reproducible procedure for the standardization of the cell density of an Aspergillus suspension. J Med Microbiol
53: 783-786
[Abstract]
[Full Text]
-
Fernandez-Torres, B., Inza, I., Guarro, J.
(2003). Comparison of In Vitro Antifungal Susceptibilities of Conidia and Hyphae of Dermatophytes with Thick-Wall Macroconidia. Antimicrob. Agents Chemother.
47: 3371-3372
[Full Text]
-
Favre, B., Hofbauer, B., Hildering, K.-S., Ryder, N. S.
(2003). Comparison of In Vitro Activities of 17 Antifungal Drugs against a Panel of 20 Dermatophytes by Using a Microdilution Assay. J. Clin. Microbiol.
41: 4817-4819
[Abstract]
[Full Text]
-
Espinel-Ingroff, A., Fothergill, A., Peter, J., Rinaldi, M. G., Walsh, T. J.
(2002). Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study. J. Clin. Microbiol.
40: 3204-3208
[Abstract]
[Full Text]
-
Hammer, K. A., Carson, C. F., Riley, T. V.
(2002). In vitro activity of Melaleuca alternifolia (tea tree) oil against dermatophytes and other filamentous fungi. J Antimicrob Chemother
50: 195-199
[Abstract]
[Full Text]
-
Vitale, R. G., Mouton, J. W., Afeltra, J., Meis, J. F. G. M., Verweij, P. E.
(2002). Method for Measuring Postantifungal Effect in Aspergillus Species. Antimicrob. Agents Chemother.
46: 1960-1965
[Abstract]
[Full Text]
-
Gonzalez, G. M., Tijerina, R., Sutton, D. A., Graybill, J. R., Rinaldi, M. G.
(2002). In Vitro Activities of Free and Lipid Formulations of Amphotericin B and Nystatin against Clinical Isolates of Coccidioides immitis at Various Saprobic Stages. Antimicrob. Agents Chemother.
46: 1583-1585
[Abstract]
[Full Text]
-
Cenci, E., Mencacci, A., Spreca, A., Montagnoli, C., Bacci, A., Perruccio, K., Velardi, A., Magliani, W., Conti, S., Polonelli, L., Romani, L.
(2002). Protection of Killer Antiidiotypic Antibodies against Early Invasive Aspergillosis in a Murine Model of Allogeneic T-Cell-Depleted Bone Marrow Transplantation. Infect. Immun.
70: 2375-2382
[Abstract]
[Full Text]
-
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Warnock, D. W.
(2001). Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin. Microbiol. Rev.
14: 643-658
[Abstract]
[Full Text]
-
Fernandez-Torres, B., Carrillo, A. J., Martin, E., Del Palacio, A., Moore, M. K., Valverde, A., Serrano, M., Guarro, J.
(2001). In Vitro Activities of 10 Antifungal Drugs against 508 Dermatophyte Strains. Antimicrob. Agents Chemother.
45: 2524-2528
[Abstract]
[Full Text]
-
Pujol, I., Fernandez-Ballart, J., Guarro, J.
(2001). Effect of inoculum form on in vitro antifungal susceptibilities of Aspergillus spp.. J Antimicrob Chemother
47: 715-718
[Abstract]
[Full Text]
-
Espinel-Ingroff, A.
(2001). In Vitro Fungicidal Activities of Voriconazole, Itraconazole, and Amphotericin B against Opportunistic Moniliaceous and Dematiaceous Fungi. J. Clin. Microbiol.
39: 954-958
[Abstract]
[Full Text]
-
Espinel-Ingroff, A.
(2001). Germinated and Nongerminated Conidial Suspensions for Testing of Susceptibilities of Aspergillus spp. to Amphotericin B, Itraconazole, Posaconazole, Ravuconazole, and Voriconazole. Antimicrob. Agents Chemother.
45: 605-607
[Abstract]
[Full Text]
-
Lass-Flörl, C., Nagl, M., Speth, C., Ulmer, H., Dierich, M. P., Würzner, R.
(2001). Studies of In Vitro Activities of Voriconazole and Itraconazole against Aspergillus Hyphae Using Viability Staining. Antimicrob. Agents Chemother.
45: 124-128
[Abstract]
[Full Text]
-
Perea, S., Fothergill, A. W., Sutton, D. A., Rinaldi, M. G.
(2001). Comparison of In Vitro Activities of Voriconazole and Five Established Antifungal Agents against Different Species of Dermatophytes Using a Broth Macrodilution Method. J. Clin. Microbiol.
39: 385-388
[Abstract]
[Full Text]